Presenting a mock-up of an injectable pen of Saxenda during its launch are (from left): Novo Nordisk Malaysia Clinical, Medical, Regulatory and Quality head Dr Shweta Uppal, Abela, Dr Pedersen and Dr Zanariah.
Obesity affects about 650 million adults across the globe and constitutes a significant public health issue worldwide. In Malaysia, the numbers are equally alarming – based on the 2015 National Health and Morbidi-ty Survey (NHMS), one out of three adults over the age of 18 are overweight, and 30.6% are obese.
“Obesity is a chronic medical condition that is known to cause serious health complications such as type 2 diabetes, cardiovascular complications, high blood pressure, and even cancers. It is also associated with lower life expectancy and impaired quality of life.
Limited time offer:
Just RM5 per month.
